{
  "data": [
    {
      "drug_id": "drug-id-0",
      "name": "DrugA0",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase I",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-1",
      "name": "DrugB0",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-2",
      "name": "DrugC0",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-3",
      "name": "DrugD0",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase I",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-4",
      "name": "DrugE0",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase II",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-5",
      "name": "DrugF0",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-6",
      "name": "DrugG0",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase I",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-7",
      "name": "DrugH0",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-8",
      "name": "DrugI0",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-9",
      "name": "DrugJ0",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-10",
      "name": "DrugK0",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-11",
      "name": "DrugL0",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-12",
      "name": "DrugM0",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-13",
      "name": "DrugN0",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase I",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-14",
      "name": "DrugO0",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase II",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-15",
      "name": "DrugP0",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase I",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-16",
      "name": "DrugQ0",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-17",
      "name": "DrugR0",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase I",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-18",
      "name": "DrugS0",
      "status": "Approved",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-19",
      "name": "DrugT0",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase I",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-20",
      "name": "DrugU0",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase II",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-21",
      "name": "DrugV0",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-22",
      "name": "DrugW0",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-23",
      "name": "DrugX0",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-24",
      "name": "DrugY0",
      "status": "Approved",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-25",
      "name": "DrugZ0",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-26",
      "name": "DrugA1",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase I",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-27",
      "name": "DrugB1",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase II",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-28",
      "name": "DrugC1",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-29",
      "name": "DrugD1",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-30",
      "name": "DrugE1",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-31",
      "name": "DrugF1",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-32",
      "name": "DrugG1",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase I",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-33",
      "name": "DrugH1",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase III",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-34",
      "name": "DrugI1",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-35",
      "name": "DrugJ1",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase II",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-36",
      "name": "DrugK1",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-37",
      "name": "DrugL1",
      "status": "In Development",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-38",
      "name": "DrugM1",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-39",
      "name": "DrugN1",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-40",
      "name": "DrugO1",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase II",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-41",
      "name": "DrugP1",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase II",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-42",
      "name": "DrugQ1",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase I",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-43",
      "name": "DrugR1",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-44",
      "name": "DrugS1",
      "status": "In Development",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-45",
      "name": "DrugT1",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase I",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-46",
      "name": "DrugU1",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-47",
      "name": "DrugV1",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase I",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-48",
      "name": "DrugW1",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-49",
      "name": "DrugX1",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase II",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-50",
      "name": "DrugY1",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase III",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-51",
      "name": "DrugZ1",
      "status": "In Development",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase I",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-52",
      "name": "DrugA2",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase II",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-53",
      "name": "DrugB2",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase I",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-54",
      "name": "DrugC2",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-55",
      "name": "DrugD2",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase I",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-56",
      "name": "DrugE2",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-57",
      "name": "DrugF2",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-58",
      "name": "DrugG2",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase II",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-59",
      "name": "DrugH2",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-60",
      "name": "DrugI2",
      "status": "Approved",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-61",
      "name": "DrugJ2",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase III",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-62",
      "name": "DrugK2",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase II",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-63",
      "name": "DrugL2",
      "status": "Approved",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-64",
      "name": "DrugM2",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase I",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-65",
      "name": "DrugN2",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase I",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-66",
      "name": "DrugO2",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-67",
      "name": "DrugP2",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase I",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-68",
      "name": "DrugQ2",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase I",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-69",
      "name": "DrugR2",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-70",
      "name": "DrugS2",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-71",
      "name": "DrugT2",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase II",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-72",
      "name": "DrugU2",
      "status": "In Development",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase II",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-73",
      "name": "DrugV2",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase I",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-74",
      "name": "DrugW2",
      "status": "Approved",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-75",
      "name": "DrugX2",
      "status": "Approved",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase II",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-76",
      "name": "DrugY2",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase II",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-77",
      "name": "DrugZ2",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-78",
      "name": "DrugA3",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase I",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-79",
      "name": "DrugB3",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase I",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-80",
      "name": "DrugC3",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase II",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-81",
      "name": "DrugD3",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Acts on serotonin reuptake inhibitors.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase I",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-82",
      "name": "DrugE3",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-83",
      "name": "DrugF3",
      "status": "Approved",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase III",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-84",
      "name": "DrugG3",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-85",
      "name": "DrugH3",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase II",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-86",
      "name": "DrugI3",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-87",
      "name": "DrugJ3",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase II",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "IV drip"
      }
    },
    {
      "drug_id": "drug-id-88",
      "name": "DrugK3",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-89",
      "name": "DrugL3",
      "status": "Approved",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase I",
        "indications": ["Rheumatoid arthritis", "Crohn's disease"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-90",
      "name": "DrugM3",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase I",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-91",
      "name": "DrugN3",
      "status": "In Development",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "HeartWell Pharma",
        "trial_Phase": "Phase I",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-92",
      "name": "DrugO3",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-93",
      "name": "DrugP3",
      "status": "Approved",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase III",
        "indications": ["Cancer", "Leukemia"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-94",
      "name": "DrugQ3",
      "status": "Approved",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Inhibits TNF-alpha.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "ImmunoLife Corp.",
        "trial_Phase": "Phase III",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-95",
      "name": "DrugR3",
      "status": "Approved",
      "description": "Prevents blood clots in high-risk patients.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Abdominal pain", "Mild anxiety"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase III",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Oral tablet"
      }
    },
    {
      "drug_id": "drug-id-96",
      "name": "DrugS3",
      "status": "In Development",
      "description": "Targets cancer cells with precision.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Sleep disturbances", "Injection site reactions"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase I",
        "indications": ["Stroke prevention", "Acute coronary syndrome"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-97",
      "name": "DrugT3",
      "status": "In Development",
      "description": "Reduces inflammation and immune response.",
      "mechanism_of_action": "Targets B-cell pathways.",
      "side_effects": ["Fatigue", "Increased risk of infections"],
      "other_details": {
        "manufacturer": "OncoTarget Therapeutics",
        "trial_Phase": "Phase III",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Topical cream"
      }
    },
    {
      "drug_id": "drug-id-98",
      "name": "DrugU3",
      "status": "In Development",
      "description": "Designed for cognitive enhancement.",
      "mechanism_of_action": "Blocks P2Y12 receptor.",
      "side_effects": ["Bleeding", "Mild sedation"],
      "other_details": {
        "manufacturer": "PharmaGenix Inc.",
        "trial_Phase": "Phase III",
        "indications": ["Chronic pain", "Neuropathic pain"],
        "formulation": "Injection"
      }
    },
    {
      "drug_id": "drug-id-99",
      "name": "DrugV3",
      "status": "In Development",
      "description": "A novel treatment for chronic pain.",
      "mechanism_of_action": "Modulates NMDA receptors.",
      "side_effects": ["Nausea", "Dizziness", "Headache"],
      "other_details": {
        "manufacturer": "NeuroGen Labs",
        "trial_Phase": "Phase II",
        "indications": ["Alzheimer’s disease", "Mild cognitive impairment"],
        "formulation": "Topical cream"
      }
    }
  ]
}
